Results 261 to 270 of about 186,761 (273)

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Lancet, The, 2016
Roy S Herbst, Paul Baas, Dong-Wan Kim
exaly  

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of Oncology, 2019
David W Cescon, Giuseppe Curigliano, Sherene Loi   +2 more
exaly  

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Lancet, The, 2014
Caroline Robert, Antoni Ribas, Omid Hamid   +2 more
exaly  

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Blood, 2019
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee   +2 more
exaly  

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Annals of Oncology, 2016
Enriqueta Felip, Federico Cappuzzo
exaly  

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Annals of Oncology
Joyce O'Shaughnessy
exaly  

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Lancet, The, 2019
Barbara Burtness, Kevin J Harrington, Richard F Greil   +2 more
exaly  

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of Oncology, 2017
Enriqueta Felip, Matthew D Hellmann, Edward B Garon   +2 more
exaly  

First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non–small-cell Lung Cancer: A Systematic Review and Network Meta-analysis

Clinical Lung Cancer, 2019
Ryul Kim, Bhumsuk Keam, Seokyung Hahn
exaly  

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

Annals of Oncology
Georgina V Long
exaly